HotSpot Therapeutics announces FDA clearance of IND application for HST-1011, an investigational small molecule allosteric inhibitor of CBL-B

Clinical Impact

Jan 3

Written By Frances Benson

https://www.hotspotthera.com/press_release/hotspot-therapeutics-announces-fda-clearance-of-ind-application-for-hst-1011-an-investigational-small-molecule-allosteric-inhibitor-of-cbl-b/

2023

Frances Benson

Akamis Bio raises $30M financing and relaunches with name change from PsiOxus Therapeutics

Nimbus Therapeutics TYK2 program to be acquired by Takeda for $4B in upfront cash and up to $2B in potential commercial milestone payments